Seagen Inc.

Seagen Inc. logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Public, Subsidiary
Established
1998-01-01
Employees
3.2K
Market Cap
-
Website
http://www.seagen.com

A Safety Study of SGN-CD19A for B-Cell Lymphoma

First Posted Date
2013-02-07
Last Posted Date
2017-10-19
Lead Sponsor
Seagen Inc.
Target Recruit Count
64
Registration Number
NCT01786135
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Stanford Cancer Center, Stanford, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 3 locations

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

First Posted Date
2013-01-28
Last Posted Date
2021-11-30
Lead Sponsor
Seagen Inc.
Target Recruit Count
452
Registration Number
NCT01777152
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Weill Cornell Medical College, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States

๐Ÿ‡ฎ๐Ÿ‡ฑ

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

and more 141 locations

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

First Posted Date
2012-10-30
Last Posted Date
2024-06-11
Lead Sponsor
Seagen Inc.
Target Recruit Count
131
Registration Number
NCT01716806
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Wenatchee Valley Medical Center, Wenatchee, Washington, United States

๐Ÿ‡บ๐Ÿ‡ธ

James Cancer Hospital / Ohio State University, Columbus, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Swedish Cancer Institute, Seattle, Washington, United States

and more 51 locations

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2012-09-03
Last Posted Date
2014-01-28
Lead Sponsor
Seagen Inc.
Target Recruit Count
4
Registration Number
NCT01677390
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Stanford Cancer Center, Stanford, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Rocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

First Posted Date
2011-10-28
Last Posted Date
2016-03-04
Lead Sponsor
Seagen Inc.
Target Recruit Count
84
Registration Number
NCT01461538
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic Cancer Center, Jacksonville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Ocala Oncology Center, Ocala, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northwest Cancer Specialists, P.C., Tulatin, Oregon, United States

and more 26 locations

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

First Posted Date
2011-08-23
Last Posted Date
2016-11-28
Lead Sponsor
Seagen Inc.
Target Recruit Count
176
Registration Number
NCT01421667
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Northwestern University, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Stanford Cancer Center, Stanford, California, United States

and more 31 locations

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

First Posted Date
2011-03-07
Last Posted Date
2017-06-28
Lead Sponsor
Seagen Inc.
Target Recruit Count
39
Registration Number
NCT01309789
Locations
๐Ÿ‡บ๐Ÿ‡ธ

UAB Comprehensive Cancer Center, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

City of Hope National Medical Center, Duarte, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Stanford Cancer Center, Stanford, California, United States

and more 8 locations

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

First Posted Date
2010-09-08
Last Posted Date
2020-09-21
Lead Sponsor
Seagen Inc.
Registration Number
NCT01196208
Locations
๐Ÿ‡บ๐Ÿ‡ธ

MD Anderson Cancer Center / University of Texas, Houston, Texas, United States

๐Ÿ‡ง๐Ÿ‡ฌ

Specializirana bolnica aktivno lechenie detsa ohcohematologichni zabolyavania Hematologichno, Sofia, Bulgaria

๐Ÿ‡ต๐Ÿ‡ฑ

Centrum Onkologii Institut im. Marii Sklodowskiej-Curie, Warsaw, Poland

and more 28 locations

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-07-21
Last Posted Date
2013-08-27
Lead Sponsor
Seagen Inc.
Target Recruit Count
51
Registration Number
NCT01166490
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Texas Oncology - Tyler, Tyler, Texas, United States

and more 4 locations

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-04-09
Last Posted Date
2021-05-14
Lead Sponsor
Seagen Inc.
Target Recruit Count
329
Registration Number
NCT01100502
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland Clinic, The, Cleveland, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 84 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath